FDA Asks Input on Controlling Nasty New Synthetic Drugs Globally
Published Date: 2/27/2026
Notice
Summary
The FDA is asking for your thoughts on new international rules to control some powerful drugs like N-Pyrrolidino Isotonitazene and MDMB-FUBINACA. These changes could affect drug makers, distributors, and countries worldwide by tightening how these substances are made and shared. Comments are open until March 5, 2026, so jump in now to help shape the U.S. stance before a big UN meeting in March!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Controls aimed at protecting public health
The U.N. Committee recommended adding N‑Pyrrolidino Isotonitazene and N‑Desethyl Etonitazene to Schedule I (1961), retaining coca leaf in Schedule I (1961), and adding MDMB‑FUBINACA to Schedule II (1971). The substances are described in the notice as highly potent, linked to fatal overdoses, and without recognized therapeutic use; the proposals will be considered at the CND meeting March 9–13, 2026.
International manufacturing and distribution limits
The U.N. review recommends international manufacturing and distribution restrictions for several substances, including N‑Pyrrolidino Isotonitazene, N‑Desethyl Etonitazene, MDMB‑FUBINACA, and coca leaf. These recommendations will be considered at the U.N. meeting March 9–13, 2026, and could tighten how makers and distributors handle those substances.
No additional U.S. domestic scheduling needed
The notice states that N‑Pyrrolidino Isotonitazene and N‑Desethyl Etonitazene are already controlled in Schedule I under the U.S. Controlled Substances Act and would not require additional permanent domestic controls if placed in Schedule I internationally. It also states MDMB‑FUBINACA is controlled in Schedule I under the CSA and would not require additional permanent domestic controls if placed in Schedule II internationally, and that domestic scheduling actions for coca leaf will not be necessary regardless of the international vote.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-03913 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on March 31 and April 1, 2026, to review important grant applications. These meetings protect private info and trade secrets while deciding who gets funding for exciting health research. Scientists and applicants should note these dates as they impact which projects get money and support.
Next: 2026-03915 — Self-Regulatory Organizations; The Options Clearing Corporation; Notice of Filing of Proposed Rule Change by The Options Clearing Corporation Concerning a Change in Types of Acceptable Collateral and an Update To Mitigate Wrong-Way Risk
The Options Clearing Corporation (OCC) is updating its rules to stop accepting two types of rarely used collateral and to better protect itself from risky situations where things could go wrong at the same time. This change affects the financial firms that use OCC to clear their options trades and helps keep the system safer without changing costs right now. The new rules were proposed in February 2026 and are open for public comments before they take effect.